CAMBRIDGE, Mass. / Apr 12, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 45,000 shares of its... Read More

Pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy on track to report topline data in 4Q 2024 Announced FDA clearance of IND application to initiate Phase 2 proof-of-concept trial with apitegromab to treat obesity; expected to commence in mid-2024 Presented preclinical data supporting potential benefit of SRK-439 to preserve lean muscle mass as part of healthier weight management at Keystone Symposia... Read More

CAMBRIDGE, Mass. / Mar 15, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards on March 11, 2024, covering an aggregate of... Read More

CAMBRIDGE, Mass. / Feb 28, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in and attend the following upcoming investor conferences in March: TD... Read More

CAMBRIDGE, Mass. / Feb 16, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 131,688 shares of... Read More

CAMBRIDGE, Mass. / Feb 15, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointment of Katie Peng to Scholar Rock’s Board of Directors and the promotion of Mo Qatanani, Ph.D.,... Read More

Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolism Scholar Rock’s novel myostatin inhibitor, SRK-439, is part of its growing, industry-leading portfolio of innovative, highly selective anti-myostatin treatments under development CAMBRIDGE, Mass. / Feb 06, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company... Read More

SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disorders Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss CAMBRIDGE, Mass. / Jan 25, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic... Read More

Randomized Phase 2 proof-of-concept trial with apitegromab in patients with obesity on GLP-1 therapies on track to initiate mid-2024 Study aims to show the importance of selective myostatin inhibition in preservation of lean muscle mass as part of healthy, safe weight loss management Scholar Rock is also developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity... Read More

CAMBRIDGE, Mass. / Jan 12, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to one newly hired employee, consisting of inducement... Read More

Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to treat spinal muscular atrophy (SMA) and cardiometabolic disorders Completed enrollment for apitegromab pivotal Phase 3 SAPPHIRE trial in patients with SMA; topline data anticipated in 4Q 2024 Apitegromab Phase 2 proof-of-concept trial in obesity expected to commence in mid-2024 Presenting new preclinical... Read More

CAMBRIDGE, Mass. / Dec 19, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 42 nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m. ET). A live webcast of the presentation... Read More

CAMBRIDGE, Mass. / Dec 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 78,576 shares of its common stock to 6 newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Nov 17, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 13,125 shares of its common stock to one newly hired employee, consisting of inducement... Read More

Completed enrollment for pivotal Phase 3 SAPPHIRE trial evaluating apitegromab; topline data expected in 4Q 2024 Expanding into cardiometabolic disorders with SRK-439, a novel investigational myostatin inhibitor Presented new data supporting proof of concept for SRK-181 in heavily pretreated patients with resistant metastatic ccRCC; completing enrollment of the Phase 1 DRAGON trial in December 2023 Completed $98 million... Read More

Promising anti-tumor activity in heavily pretreated clear cell renal cell carcinoma (ccRCC) patients Objective response rate (ORR) of 21.4% and disease control rate of 57% Biomarker data supports proof of mechanism across multiple tumor types Combination therapy of SRK-181 and pembrolizumab was generally well tolerated Company to discuss SRK-181 program during conference call on third quarter 2023 financial results and... Read More

CAMBRIDGE, Mass. / Nov 02, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Truist Securities BioPharma Symposium on Thursday, November 9, 2023, from 10:45-11:30 a.m. ET.... Read More

Poster presentations to include safety, efficacy, and biomarker data from Part A and B of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 CAMBRIDGE, Mass. / Oct 19, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it will... Read More

CAMBRIDGE, Mass. / Oct 11, 2023 / Business Wire / Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 12,408,760 shares of its common stock at a public offering price of $6.85 per share. The aggregate... Read More

CAMBRIDGE, Mass. / Oct 11, 2023 / Business Wire / Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has commenced an underwritten public offering for $75.0 million of shares of its common stock. All of the shares are being offered by Scholar Rock. In... Read More

Company plans to expand into cardiometabolic disorders, leveraging its experience in myostatin inhibition Preclinical data support advancing SRK-439, a novel investigational myostatin inhibitor for the treatment of cardiometabolic disorders, with an initial focus on obesity, towards an IND submission in 2025 To inform the development of SRK-439, Company plans to initiate a Phase 2 proof-of-concept trial of apitegromab in... Read More

Topline data from Phase 3 trial expected in Q4 2024 Company to present encore 36-month efficacy, safety, and patient-reported outcomes data from the Phase 2 TOPAZ trial extension at the 2023 World Muscle Society (WMS) Annual Congress Apitegromab is the only muscle-targeted therapy candidate with clinical data showing proof of concept in spinal muscular atrophy CAMBRIDGE, Mass. / Sep 19, 2023 / Business Wire / Scholar Rock... Read More

CAMBRIDGE, Mass. / Sep 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 8,750 shares of its common stock to one newly hired employee, consisting of inducement... Read More

CAMBRIDGE, Mass. / Aug 18, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 150,938 shares of its common stock to 8 newly hired employees, consisting of inducement... Read More

Recently presented 36-month apitegromab extension data from Phase 2 TOPAZ trial demonstrate long-term substantial and sustained improvement of motor function and further strengthen conviction in pivotal Phase 3 SAPPHIRE trial Pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track to complete enrollment in Q3 2023 with top-line data expected in 2H 2024 Clinical and biomarker update from the Part B portion of the Phase... Read More

CAMBRIDGE, Mass. / Jul 13, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 72,625 shares of its common stock to 6 newly hired employees, consisting of inducement... Read More

Improvements in patient-reported outcomes consistent with gains in motor function scores Safety profile at 36 months consistent with previous reports with no new safety findings; more than 90 percent of nonambulatory patients remained on study Enrollment progressing in pivotal Phase 3 SAPPHIRE registrational trial, anticipated completion in Q3 2023 Scholar Rock to host virtual investor event on July 12 at 9:00 AM EST to... Read More

CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 216,563 shares of its common stock to 8 newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Jun 01, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:00 p.m. ET. A live webcast of the presentation may be accessed by visiting the... Read More

CAMBRIDGE, Mass. / May 10, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 49,176 shares of its common stock to four newly hired employees, consisting of inducement... Read More

Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023 Upcoming presentations of 36-month apitegromab data from Phase 2 TOPAZ trial at Cure SMA’s Annual Research & Clinical Conference Continued advancement of Phase 1 DRAGON trial of SRK-181; biomarker and clinical data update planned in the second half of 2023 Approximately $275 million in cash, cash equivalents, and marketable... Read More

Apitegromab is the only muscle-targeted therapy to demonstrate proof of concept in spinal muscular atrophy Two oral presentations to cover long-term efficacy, safety, and patient-reported outcome data CAMBRIDGE, Mass. / May 08, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental... Read More

CAMBRIDGE, Mass. / Apr 12, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 83,125 shares of its common stock to five newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Apr 10, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Richard Brudnick, has been appointed to Scholar Rock’s Board of Directors... Read More

CAMBRIDGE, Mass. / Mar 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to 1 newly hired employee, consisting of inducement... Read More

CAMBRIDGE, Mass. / Mar 01, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab, an investigational selective... Read More

CAMBRIDGE, Mass. / Feb 27, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET. A live webcast of the presentation may be accessed by... Read More

CAMBRIDGE, Mass. / Feb 17, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Feb 06, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M. Sacco as Chief Commercial Officer. Ms. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial... Read More

Pivotal Phase 3 SAPPHIRE trial enrollment completion expected in 2023 Phase 1 DRAGON trial of SRK-181 continues to advance with presented data that showed early indications of efficacy; ongoing clinical data updates planned in 2023 Anticipated cash runway into 2025 Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play... Read More

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 41 st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET). A live webcast of the presentation may be accessed by visiting the Investors & Media... Read More